Menu

狄诺塞麦入医保了吗?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

The U.S. FDA has approved denosumab to prevent skeletal-related events (SREs) in cancer patients whose cancer has metastasized and damaged bone. So-called bone-related events include fractures and pain caused by cancer.

So, is denosumab covered by medical insurance?

In May 2019, denosumab was approved for marketing in the country. However, because it was conditionally approved and it was only on the market for five months, it is difficult to buy it in the country. Therefore, there is no medical insurance reimbursement!

Currently, denosumab on the market in the United States is 60mg/1ml tube/box, priced at US$1,169.98. It is relatively expensive, and most families of patients with average economic levels cannot afford the high medical expenses.

Fortunately, denosumab produced by Amgen of the United States has been launched in Turkey. The specification is 125mg/1ml tube/box. The price is equivalent to RMB 3,000, which can be said to be high quality and low price. Therefore, more and more patients are choosing denosumab, which is marketed in Türkiye by Amgen of the United States.

Recommended usage and dosage of denosumab:

(1) Denosumab can only be injected subcutaneously, not intravenously, intramuscularly or intradermally.

(2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen.

(3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and another 120 mg on day 8 and day 15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia.

(5) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and 120 mg on day 8 and day 15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

The most common adverse reactions (≥25%) in patients with bone metastases from solid tumors were fatigue/asthenia, hypophosphatemia, and nausea.

Common adverse reactions (≥10%) in patients with giant cell tumor of bone include headache, joint pain, nausea, back pain, fatigue, and extremity pain.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。